These and other early studies ultimately led to both the development of TRBAs to engage and redirect T-cells to induce serial killing of antigen-specific, targeted cancer cells [20] and to the genetic engineering of autologous T-cells to empower them with cancer cell surface antigen-specific targeting antibody-based receptors (i.e., CARs) fused to T-cell activating domains [35,36,37]. Here, CD53 is linked to cancer.